UnknownPhase 3

Clinical Study of Clevidipine Butyrate Injection in the Treatment of Hypertensive Emergency and Sub-emergency

China10 participantsStarted 2021-10-11

Plain-language summary

Emergency treatment warning of clevidipine butyrate butyrate injection or invalid medical treatment and verification of the effectiveness and safety of subacute.

Who can participate

Age range

18 Years – 75 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

. 18 years old ≤ age ≤ 75 years old, men and women are not restricted;
. Hypertensive emergency and hypertensive sub-emergency patients who are not suitable for oral antihypertensive treatment or oral antihypertensive treatment are ineffective and require intravenous medication to quickly control blood pressure, and meet one of the following conditions: ① Consultation systolic blood pressure (SBP)\> Patients with 180mmHg and/or consulting room diastolic blood pressure (DBP)\> 120mmHg, with or without target organ damage;
. To participate in this clinical trial voluntarily, the subject (or legal representative) signs an informed consent form.

Exclusion criteria

. Those who cannot receive intravenous infusion of antihypertensive drugs for 18 hours or more;
. Patients with severe lipid metabolism abnormalities (such as triglycerides\> 5mmol/L, familial hypercholesterolemia, lipid nephropathy, or acute pancreatitis accompanied by hyperlipidemia);
. Patients who are known to have severe liver insufficiency or a history of liver failure or cirrhosis;
. Patients who are known to be intolerant or allergic to study drugs or calcium channel blockers, or are allergic to the ingredients of study drug excipients, or are allergic to soybeans, soy products, eggs and egg products;
. Patients with known or suspected severe aortic stenosis;

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

The percentage of patients whose systolic blood pressure dropped to the target range within 30 minutes of starting the infusion.

Timeframe: 30 minutes

Trial details

NCT IDNCT05044364

SponsorShenzhen People's Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2022-04-01

Contact for this trial

JIN XIAOHUI, 34

18645005162 517026400@163.com

View on ClinicalTrials.gov More Hypertensive Emergency trials